Efficacy of adalimumab combined with Tripterygium wilfordii Hook F in the treatment of patient with rheumatoid arthritis: A multicenter, open‐label, randomized‐controlled trial

Abstract

AbstractObjectivesTo evaluate the efficacy and safety of adalimumab (ADA) combined with Tripterygium wilfordii Hook F (TwHF) in the treatment of methotrexate (MTX)‐inadequate response patients with rheumatoid arthritis (RA).MethodsIn this multicenter, open‐label, randomized controlled clinical trial, 64 RA patients with inadequate response to MTX were 1:1 randomly assigned into treatment or control groups. The treatment group was treated with ADA in combination with TwHF, and the control group was treated with ADA in combination with MTX for 24 weeks. The primary endpoint was the percentage of patients having low disease activity (2.6 ≤ DAS28‐ESR < 3.2) and remission rates (DAS28‐ESR < 2.6) at week 24.ResultsIn total, 53 of the 64 patients (82.8%) completed this 24‐week clinical trial. By intent‐to‐treat (ITT) analysis, a comparable outcome was observed between the two groups. The percentage of patients achieving low disease activity in the treatment group and control group were 43.8% and 46.9% (95% CI, 21.28 to 27.48, p = .802). Percentage of patients achieving low disease activity rates were respectively 28.1% and 31.3% in the treatment group and control group (95% CI, 19.18 to 25.58, p = .784). In per‐protocol (PP) analysis, the results were consistent with the ITT model. The incidence of adverse events was comparable between the two groups.ConclusionsThere were no significant differences in efficacy and safety between ADA combined with TwHF versus ADA combined with MTX in the treatment of RA. TwHF might be an alternative treatment for RA patients who are intolerant to MTX.